NDATOPICALCREAM
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Data completeness
7/8 — Comprehensive
LUZU (luliconazole) by Bausch + Lomb is cytochrome p450 2c19 inhibitors [moa]. Approved for azole antifungal [epc]. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUZU is a topical azole antifungal cream containing luliconazole, approved in 2013 for treating tinea pedis, tinea cruris, and tinea corporis (fungal skin infections of the feet, groin, and body). It works by inhibiting fungal cytochrome P450 2C19, disrupting ergosterol synthesis and causing fungal cell membrane damage.
$0.018BPart D
Peak8.0 years to LOELUZU is in peak commercial phase with minimal Part D engagement ($18K annually), suggesting a niche market presence with modest sales team requirements at Bausch + Lomb.
Mechanism of Action
Cytochrome P450 2C19 Inhibitors
Pharmacologic Class:
Azole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
Started Jan 2021
589 enrolled
Obsessive-Compulsive Disorder
Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
Started Feb 2016
75 enrolled
Tinea Corporis
Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
Started Dec 2015
30 enrolled
Tinea PedisTinea Cruris
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Started Feb 2015
20 enrolled
Tinea PedisTinea Cruris
Worked on LUZU at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.